Marker Therapeutics rises on pre-clinical data from cancer therapy

Marker Therapeutics

31/05/2023 12:17

** Shares of cancer immunotherapy developer Marker
Therapeutics Inc  MRKR.O  rise 13.54% to $1.51 premarket
    ** Co announces pre-clinical data from its multiple
tumor-associated antigens-specific T cell product candidate,
MT-601, in lymphoma cells
    ** Co's therapy was investigated in the Baylor TACTAL study,
which enrolled patients with both Hodgkin's and non-Hodgkin's
lymphoma, types of cancer that start in the lymphatic system
     ** Some patients who attained a complete remission with the
treatment were still in remission at the 72 months follow-up -
Co
    ** MRKR believes that the therapy may result in durable
responses due to its ability to overcome antigen loss by
targeting more than one antigen
    ** Up to last close, stock down ~50% YTD

 (Reporting by Sriparna Roy in Bengaluru)
 ((Sriparna.Roy@thomsonreuters.com;))